# 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

> **NCT02174679** · — · NO_LONGER_AVAILABLE · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Carcinoid Cancer
- Neuroendocrine Tumors
- Medullary Thyroid Cancer
- Cancers Expressing Somatostatin Receptors

## Interventions

- **DRUG:** 68Ga DOTATATE

## Key facts

- **NCT ID:** NCT02174679
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02174679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02174679, "68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02174679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*